Gastroenterology
Volume 123, Issue 3 , Pages 933-935 , September 2002

Much to do about gas

References 

  1. Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in the irritable bowel syndrome. Gastroenterology. 2002;123:700–706
  2. Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology. 2002;122:1748–1755
  3. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut. 2001;48:14–19
  4. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405–411
  5. Snape WJ, Matarazzo SA, Cohen S. Effect of eating and gastrointestinal hormones on human colonic myoelectrical and motor activity. Gastroenterology. 1978;75:373–378
  6. Feinle C, Grundy D, Read NW. Effects of duodenal nutrients on sensory and motor responses of the human stomach to distension. Am J Physiol. 1997;273:G721–G726
  7. Raybould HE, Meyer JH, Tabrizi Y, Liddle RA, Tso P. Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation. Am J Physiol. 1998;274:R1834–R1838
  8. Lal S, Kirkup AJ, Brunsden AM, Thompson DG, Grundy D. Vagal afferent responses to fatty acids of different chain length in the rat. Am J Physiol Gastrointest Liver Physiol. 2001;281:G907–G915
  9. Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut. 2001;48:347–355
  10. McLaughlin J, Grazia Luca M, Jones MN, D'Amato M, Dockray GJ, Thompson DG. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology. 1999;116:46–53
  11. Meyer JH, Tabrizi Y, DiMaso N, Hlinka M, Raybould HE. Length of intestinal contact on nutrient-driven satiety. Am J Physiol. 1998;275:R1308–R1319
  12. Hunt JN, Spurrell WR. The pattern of emptying of the human stomach. J Physiol. 1951;113:157–168
  13. Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk DB. Further characterisation of the “ileal brake” reflex in man—effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut. 1988;29:1042–1051
  14. Feinle C, Rades T, Otto B, Fried M. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology. 2001;120:1100–1107
  15. Aggarwal AM, Camilleri M, Phillips SF, Schlagheck TG, Brown ML, Thomforde GM. Olestra, a nondigestible, nonabsorbable fat. Effects on gastrointestinal and colonic transit. Dig Dis Sci. 1993;38:1009–1014
  16. Feinle C, Grundy D, Otto B, Fried M. Relationship between increasing duodenal lipid doses, gastric perception, and plasma hormone levels in humans. Am J Physiol Regul Integr Comp Physiol. 2000;278:R1217–R1223
  17. Kirkup AJ, Brunsden AM, Grundy D. Receptors and transmission in the brain-gut axis: potential for novel therapies. I. Receptors on visceral afferents. Am J Physiol Gastrointest Liver Physiol. 2001;280:G787–G794
  18. Raybould HE, Tabrizi Y, Meyer JH, Walsh JH. PYY immunoneutralization does not alter lipid-induced inhibition of gastric emptying in rats. Regul Pept. 1999;79:125–130
  19. Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther. 2001;15:525–537
  20. Kuo B, Camilleri M, Burton D, Viramontes B, McKinzie S, Thomforde G, et al. Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther. 2002;16:225–233
  21. Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther. 1994;8:403–407
  22. Kirchgessner AL. Orexins in the brain-gut axis. Endocr Rev. 2002;23:1–15
  23. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G424–G431

☆ Address requests for reprints to: Michael Camilleri, M.D., Mayo Clinic, Charlton 7-154, 200 First Street S.W., Rochester, Minnesota 55905. e-mail: camilleri.michael@mayo.edu.

☆☆ Supported by grants #R01-DK54681 and #K24-DK02638 from the National Institutes of Health (to M.C.). Dr. Camilleri has received research grants from Glaxo Wellcome, the manufacturer of Alosetron.

PII: S0016-5085(02)00181-6

Gastroenterology
Volume 123, Issue 3 , Pages 933-935 , September 2002

Article Tools